WallStSmart

Arcosa Inc (ACA)vsGE Vernova LLC (GEV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE Vernova LLC generates 1266% more annual revenue ($39.38B vs $2.88B). GEV leads profitability with a 23.8% profit margin vs 7.2%. ACA appears more attractively valued with a PEG of 1.55. GEV earns a higher WallStSmart Score of 63/100 (C+).

ACA

Buy

59

out of 100

Grade: C

Growth: 7.3Profit: 5.5Value: 4.0Quality: 6.0
Piotroski: 3/9Altman Z: 1.73

GEV

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 7.0Value: 3.7Quality: 4.3
Piotroski: 4/9Altman Z: 1.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ACASignificantly Overvalued (-20.2%)

Margin of Safety

-20.2%

Fair Value

$106.33

Current Price

$126.47

$20.14 premium

UndervaluedFair: $106.33Overvalued

Intrinsic value data unavailable for GEV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
335.3%10/10

Earnings expanding 335.3% YoY

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

GEV6 strengths · Avg: 9.2/10
Market CapQuality
$308.81B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
75.7%10/10

Every $100 of equity generates 76 in profit

EPS GrowthGrowth
1816.0%10/10

Earnings expanding 1816.0% YoY

Profit MarginProfitability
23.8%9/10

Keeps 24 of every $100 in revenue as profit

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

Free Cash FlowQuality
$4.79B8/10

Generating 4.8B in free cash flow

Areas to Watch

ACA4 concerns · Avg: 3.8/10
PEG RatioValuation
1.554/10

Expensive relative to growth rate

P/E RatioValuation
27.5x4/10

Moderate valuation

Altman Z-ScoreHealth
1.734/10

Distress zone — elevated risk

Profit MarginProfitability
7.2%3/10

7.2% margin — thin

GEV4 concerns · Avg: 2.5/10
P/E RatioValuation
33.5x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
3.742/10

Expensive relative to growth rate

Price/BookValuation
20.5x2/10

Trading at 20.5x book value

Altman Z-ScoreHealth
1.022/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ACA

The strongest argument for ACA centers on EPS Growth, Price/Book.

Bull Case : GEV

The strongest argument for GEV centers on Market Cap, Return on Equity, EPS Growth. Profitability is solid with margins at 23.8% and operating margin at 5.5%. Revenue growth of 16.3% demonstrates continued momentum.

Bear Case : ACA

The primary concerns for ACA are PEG Ratio, P/E Ratio, Altman Z-Score.

Bear Case : GEV

The primary concerns for GEV are P/E Ratio, PEG Ratio, Price/Book.

Key Dynamics to Monitor

ACA profiles as a value stock while GEV is a growth play — different risk/reward profiles.

GEV carries more volatility with a beta of 1.20 — expect wider price swings.

GEV is growing revenue faster at 16.3% — sustainability is the question.

GEV generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

GEV scores higher overall (63/100 vs 59/100), backed by strong 23.8% margins and 16.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arcosa Inc

INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA

Arcosa, Inc. provides infrastructure related products and solutions for the construction, energy and transportation markets in North America. The company is headquartered in Dallas, Texas.

Visit Website →

GE Vernova LLC

INDUSTRIALS · SPECIALTY INDUSTRIAL MACHINERY · USA

GE Vernova LLC, an energy business company, generates electricity.

Visit Website →

Want to dig deeper into these stocks?